- Conditions
- Brain and Central Nervous System Tumors, Neurotoxicity
- Interventions
- temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 9,247
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 17
- States / cities
- Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
- Conditions
- Asthma
- Interventions
- Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 100
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Interventions
- Angel® Catheter
- Device
- Lead sponsor
- BiO2 Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Jackson, Mississippi • Portland, Oregon • Dallas, Texas + 1 more
- Conditions
- Covid19
- Interventions
- T-Detect COVID test
- Device
- Lead sponsor
- Adaptive Biotechnologies
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 12 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Uveitis
- Interventions
- Brepocitinib PO QD, Placebo PO QD
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Talazoparib
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 561
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 362 more
- Conditions
- Chronic Pain
- Interventions
- The MySupport tool
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Contraception
- Interventions
- Misoprostol, Magnesium Oxide
- Drug · Dietary Supplement
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Portland, Oregon
- Conditions
- Bowel Dysfunction, Constipation
- Interventions
- Placebo, Alvimopan, Alviompan
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
- Conditions
- Stage IIIC Melanoma, Stage IV Melanoma
- Interventions
- Denileukin diftitox
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Non-radiographic Spondyloarthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
- Conditions
- Esophageal Cancer
- Interventions
- gefitinib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 119
- States / cities
- Mobile, Alabama • Jacksonville, Florida • Aurora, Illinois + 77 more
- Conditions
- Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tamoxifen Citrate, Topotecan, Trametinib Dimethyl Sulfoxide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 488
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
- Conditions
- Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
- Interventions
- Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 55
- States / cities
- Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
- Conditions
- Colon Cancer, Lynch Syndrome
- Interventions
- MSI screening test
- Procedure
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atopic Dermatitis
- Interventions
- Lebrikizumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 160
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 32
- States / cities
- Anaheim, California • Burbank, California • Concord, California + 27 more
- Conditions
- Osteoarthritis, Hip, Avascular Necrosis of Hip, Avascular Necrosis of the Femoral Head, Post-traumatic; Arthrosis
- Interventions
- Avenir Complete Femoral Stem
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 3
- States / cities
- Jackson, Mississippi • Saint Joseph, Missouri • Portland, Oregon
- Conditions
- Social Phobia
- Interventions
- AV608
- Drug
- Lead sponsor
- Avera Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Beverly Hills, California + 11 more
- Conditions
- Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
- Interventions
- 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
- Drug
- Lead sponsor
- Actuate Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
- Conditions
- Obesity
- Interventions
- Multi-Modal Education (MME), Traditional Education (TE)
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Iowa City, Iowa + 5 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Cemiplimab, Platinum-based chemotherapy, REGN7075
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 15
- States / cities
- Orange, California • Skokie, Illinois • Detroit, Michigan + 10 more